Women with COPD Experience Increased Symptom Burden, Frequent and Severe Exacerbation, and Impaired Functional Capacity as compared to Men in SPIROMICS

Lambert, Allison; Dieter, Brad P.; Barr, R. Graham; Bhatt, Surya P.; Christenson, Stephanie A.; Comellas, A.P.; Cooper, C.B.; Curtis, J.L.; Drummond, M.B.; Fawzy, Ashraf; Hoffman, Eric A.; Hu, Shaoxian; Kaner, R.J.; Kanner, Richard E.; Kim, V.; Krishnan, Jerry A.; Lazarus, Stephen C.; Neptune, Enid; Oelsner, Elizabeth C.; Ortega, Victor E.; Paine, Robert; Paulin, Laura M.; Pirozzi, C.S.; Putcha, Nirupama; Scholand, Mary Beth; Sieren, J.C.; Tashkin, D.P.; Wells, Joanna; Wilgus, M.L.; Wise, Robert A.; Hansel, Nadia N.; Han, MeiLan K.; Investigators, Spiromics

doi:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5941

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, women with COPD experienced more severe symptoms, a poorer quality of life, and reported more severe acute exacerbations then men. The SPIROMICS prospective cohort study [ 7 ], investigated the differences in COPD outcomes in relation to gender. The study included baseline data from 1832 participants with a formal diagnosis of COPD and >20 pack-years of cigarette smoking reported.…”

mentioning

confidence: 99%

Women with COPD

McIvor

Saraiva

Denning

et al. 2020

Breathe

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Women with COPD

McIvor

Saraiva

Denning

et al. 2020

Breathe

View full text Add to dashboard Cite

show abstract

“…It remains unclear whether this is also an issue with systematic reviews of digital technologies for COPD. According to the literature identified in the context of preparing this protocol, we have noticed that the terms “sex” and “gender” are not used in a standardized way in studies on COPD [ 4 , 5 , 8 - 12 ]. This is consistent with the findings of Adisso et al [ 46 ], who conducted a secondary analysis of a Cochrane systematic review that assessed sex and gender terminology in shared decision-making studies.…”

Section: Discussionmentioning

confidence: 99%

“…Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease associated with a high disease burden and premature death [1,2]. The prevalence increases with age [3], and differences in diagnostic and therapeutic responses depending on sex, gender, or age have been found [4][5][6][7][8][9][10][11][12]. For example, although females manifest more severe COPD symptoms across their life course than males [9], they also benefit to a greater extent from certain therapeutic interventions [10].…”

Section: Introductionmentioning

confidence: 99%

“…In general, sex and gender appear to be inconsistently defined in the literature on COPD. Some studies refer exclusively to sex [10][11][12], others exclusively or predominantly to gender [4,5], and some use both terms [8,9]. We refer to "sex" as a genetic or biological construct that distinguishes between males and females and to "gender" as a social construct [2,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Influence of Sex, Gender, or Age on Outcomes of Digital Technologies for Treatment and Monitoring of Chronic Obstructive Pulmonary Disease: Protocol for an Overview of Systematic Reviews

Matthias¹,

Honekamp²,

Santis³

2022

JMIR Res Protoc

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is a common chronic disease that can be treated and monitored with various digital technologies. Digital technologies offer unique opportunities for treating and monitoring people with chronic diseases, but little is known about whether the outcomes of such technologies depend on sex, gender, or age in people with COPD. Objective The general objective of this study is to assess the possible influence of sex, gender, or age on outcomes of digital technologies for treatment and monitoring of COPD through an overview of systematic reviews. Methods The study is planned as an overview of systematic reviews. Study reporting is based on the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 2020 guidelines because guidelines for overviews are not available as of this writing. The information sources for the overview will include 4 bibliographic databases (MEDLINE, Cochrane Library, Epistemonikos, and Web of Science) as well as the bibliographies of the included systematic reviews. The electronic search strategy will be developed and conducted in collaboration with an experienced database specialist. The search results will be presented in accordance with the PRISMA 2020 guidelines. The eligibility of studies is based on the population, intervention, comparison, outcomes, and study design (PICOS) criteria: (1) people with COPD (population), (2) digital technology intervention for treatment or monitoring (intervention), (3) any control group or no control group (comparison), (4) any outcome, and (5) systematic review of randomized controlled trials or non–randomized controlled trials with or without a meta-analysis (study design). Critical appraisal of the included systematic reviews will be performed using A Measurement Tool to Assess Systematic Reviews, version 2 (AMSTAR 2). Data will be extracted using a standardized data extraction sheet. Results The literature search is scheduled for June 2022. We expect to select the relevant systematic reviews, code the data, and appraise the systematic reviews by December 2022. Conclusions There is a growing recognition that the influence of sex, gender, or age should be considered in research design and outcome reporting in the context of health care interventions. Our overview will identify systematic reviews of various digital technologies for treatment or monitoring of COPD. The most interesting aspect of the overview will be to investigate if any systematic reviews considered the influence of sex, gender, or age on the outcomes of such digital technologies in COPD. Evidence from the overview could be used to guide more individualized (sex, gender, or age-based) recommendations for the use of digital technologies among people with COPD. Trial Registration PROSPERO International Prospective Register of Systematic Reviews CRD42022322924; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=322924

show abstract

“…In general, as individuals age, the likelihood of developing the condition increases [1,15], and diagnostic and therapeutic approaches vary depending on sociodemographic factors (sex, gender, or age) [8][9][10][11][12][13][16][17][18][19]. For example, although women tend to exhibit more severe symptoms of COPD than men throughout their lifespan [13], they may also respond better to specific treatments [9].…”

Section: Introductionmentioning

confidence: 99%

Consideration of Sex, Gender, or Age on Outcomes of Digital Technologies for Treatment and Monitoring of Chronic Obstructive Pulmonary Disease: Overview of Systematic Reviews

Matthias,

Honekamp,

Heinrich

et al. 2023

J Med Internet Res

View full text Add to dashboard Cite

Background Several systematic reviews have addressed digital technology use for treatment and monitoring of chronic obstructive pulmonary disease (COPD). Objective This study aimed to assess if systematic reviews considered the effects of sex, gender, or age on the outcomes of digital technologies for treatment and monitoring of COPD through an overview of such systematic reviews. The objectives of this overview were to (1) describe the definitions of sex or gender used in reviews; (2) determine whether the consideration of sex, gender, or age was planned in reviews; (3) determine whether sex, gender, or age was reported in review results; (4) determine whether sex, gender, or age was incorporated in implications for clinical practice in reviews; and (5) create an evidence map for development of individualized clinical recommendations for COPD based on sex, gender, or age diversity. Methods MEDLINE, the Cochrane Library, Epistemonikos, Web of Science, and the bibliographies of the included systematic reviews were searched to June 2022. Inclusion was based on the PICOS framework: (1) population (COPD), (2) intervention (any digital technology), (3) comparison (any), (4) outcome (any), and (5) study type (systematic review). Studies were independently selected by 2 authors based on title and abstract and full-text screening. Data were extracted by 1 author and checked by another author. Data items included systematic review characteristics; PICOS criteria; and variables related to sex, gender, or age. Systematic reviews were appraised using A Measurement Tool to Assess Systematic Reviews, version 2 (AMSTAR 2). Data were synthesized using descriptive statistics. Results Of 1439 records, 30 systematic reviews published between 2010 and 2022 were included in this overview. The confidence in the results of 25 of the 30 (83%) reviews was critically low according to AMSTAR 2. The reviews focused on user outcomes that potentially depend on sex, gender, or age, such as efficacy or effectiveness (25/30, 83%) and acceptance, satisfaction, or adherence (3/30, 10%) to digital technologies for COPD. Reviews reported sex or gender (19/30 systematic reviews) or age (25/30 systematic reviews) among primary study characteristics. However, only 1 of 30 reviews included age in a subgroup analysis, and 3 of 30 reviews identified the effects of sex, gender, or age as evidence gaps. Conclusions This overview shows that the effects of sex, gender, or age were rarely considered in 30 systematic reviews of digital technologies for COPD treatment and monitoring. Furthermore, systematic reviews did not incorporate sex, gender, nor age in their implications for clinical practice. We recommend that future systematic reviews should (1) evaluate the effects of sex, gender, or age on the outcomes of digital technologies for treatment and monitoring of COPD and (2) better adhere to reporting guidelines to improve the confidence in review results. Trial Registration PROSPERO CRD42022322924; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=322924 International Registered Report Identifier (IRRID) RR2-10.2196/40538

show abstract

Women with COPD Experience Increased Symptom Burden, Frequent and Severe Exacerbation, and Impaired Functional Capacity as compared to Men in SPIROMICS

Cited by 4 publications

References 0 publications

Women with COPD

Women with COPD

The Influence of Sex, Gender, or Age on Outcomes of Digital Technologies for Treatment and Monitoring of Chronic Obstructive Pulmonary Disease: Protocol for an Overview of Systematic Reviews

Consideration of Sex, Gender, or Age on Outcomes of Digital Technologies for Treatment and Monitoring of Chronic Obstructive Pulmonary Disease: Overview of Systematic Reviews

Contact Info

Product

Resources

About